Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Right Dose, Right Now: AutoKinetics pharmacometric model validation in ICU anti-infective therapy
NL-OMON21977Recruiting
- Sponsor
- VU University Medical Center
- Start
- Jun 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vancomycin, meropenem, ceftriaxone, cefotaxime, ciprofloxacin and 4 more in sepsis and Infectious disease (2 cohorts), sponsored by VU University Medical Center. Primary endpoints: Agreement between predicted and observed relevant pharmacometric parameters, Percentage of correct first predictions of each pharmacometric model and 1 more. Started Jun 2017; status: recruiting.
02
Drugs
vancomycinmeropenemceftriaxonecefotaximeciprofloxacin
03
Conditions
sepsisInfectious disease
Beyond the preview
Go deeper on NL-OMON21977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21977.